PortfoliosLab logoPortfoliosLab logo
MDGL vs. ELVA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

MDGL vs. ELVA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Madrigal Pharmaceuticals, Inc. (MDGL) and Electrovaya Inc. Common Shares (ELVA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, MDGL achieves a -17.44% return, which is significantly lower than ELVA's 20.25% return. Over the past 10 years, MDGL has outperformed ELVA with an annualized return of 46.09%, while ELVA has yielded a comparatively lower 2.89% annualized return.


MDGL

1D
1.37%
1M
-10.95%
YTD
-17.44%
6M
-15.87%
1Y
62.66%
3Y*
21.44%
5Y*
34.82%
10Y*
46.09%

ELVA

1D
-3.16%
1M
-0.52%
YTD
20.25%
6M
43.50%
1Y
181.07%
3Y*
37.56%
5Y*
9.63%
10Y*
2.89%
*Multi-year figures are annualized to reflect compound growth (CAGR)

MDGL vs. ELVA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
MDGL
Madrigal Pharmaceuticals, Inc.
-17.44%88.72%33.36%-20.28%242.52%-23.77%22.02%-19.17%22.80%516.04%
ELVA
Electrovaya Inc. Common Shares
20.25%218.55%-18.95%-17.30%2.78%-38.98%686.67%48.08%-80.52%-67.02%

Correlation

The correlation between MDGL and ELVA is 0.10, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.10

Correlation (3Y)
Calculated over the trailing 3-year period

0.05

Correlation (5Y)
Calculated over the trailing 5-year period

0.07

Correlation (10Y)
Calculated over the trailing 10-year period

0.05

Correlation (All Time)
Calculated using the full available price history since Jan 8, 2016

0.05

Fundamentals

Market Cap

MDGL:

$13.96B

ELVA:

$490.77M

EPS

MDGL:

-$12.87

ELVA:

$0.11

PS Ratio

MDGL:

10.21

ELVA:

6.21

PB Ratio

MDGL:

25.68

ELVA:

7.79

Total Revenue (TTM)

MDGL:

$1.13B

ELVA:

$70.74M

Gross Profit (TTM)

MDGL:

$1.05B

ELVA:

$22.01M

EBITDA (TTM)

MDGL:

-$287.63M

ELVA:

$6.86M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

MDGL vs. ELVA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MDGL
MDGL Risk / Return Rank: 7878
Overall Rank
MDGL Sharpe Ratio Rank: 8080
Sharpe Ratio Rank
MDGL Sortino Ratio Rank: 8080
Sortino Ratio Rank
MDGL Omega Ratio Rank: 7777
Omega Ratio Rank
MDGL Calmar Ratio Rank: 7777
Calmar Ratio Rank
MDGL Martin Ratio Rank: 7575
Martin Ratio Rank

ELVA
ELVA Risk / Return Rank: 8787
Overall Rank
ELVA Sharpe Ratio Rank: 8989
Sharpe Ratio Rank
ELVA Sortino Ratio Rank: 8686
Sortino Ratio Rank
ELVA Omega Ratio Rank: 8484
Omega Ratio Rank
ELVA Calmar Ratio Rank: 8888
Calmar Ratio Rank
ELVA Martin Ratio Rank: 8787
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MDGL vs. ELVA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Madrigal Pharmaceuticals, Inc. (MDGL) and Electrovaya Inc. Common Shares (ELVA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


MDGLELVADifference
Sharpe ratioReturn per unit of total volatility

-0.65

Sortino ratioReturn per unit of downside risk

-0.44

Omega ratioGain probability vs. loss probability

1.26

1.32

-0.06

Calmar ratioReturn relative to maximum drawdown

2.11

3.80

-1.68

Martin ratioReturn relative to average drawdown

4.63

9.01

-4.38

MDGL vs. ELVA - Sharpe Ratio Comparison

The current MDGL Sharpe Ratio is 1.35, which is lower than the ELVA Sharpe Ratio of 2.00. The chart below compares the historical Sharpe Ratios of MDGL and ELVA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

MDGL vs. ELVA - Drawdown Comparison

The maximum MDGL drawdown since its inception was -98.40%, roughly equal to the maximum ELVA drawdown of -96.90%. Use the drawdown chart below to compare losses from any high point for MDGL and ELVA.


Loading charts...

Drawdown Indicators


MDGLELVADifference

Max Drawdown

Largest peak-to-trough decline

-98.40%

-96.90%

-1.50%

Max Drawdown (1Y)

Largest decline over 1 year

-29.36%

-44.42%

+15.06%

Max Drawdown (3Y)

Largest decline over 3 years

-52.88%

-64.19%

+11.31%

Max Drawdown (5Y)

Largest decline over 5 years

-61.41%

-66.78%

+5.37%

Max Drawdown (10Y)

Largest decline over 10 years

-82.19%

-96.90%

+14.71%

Current Drawdown

Current decline from peak

-20.25%

-41.01%

+20.76%

Average Drawdown

Average peak-to-trough decline

-58.52%

-73.62%

+15.10%

Ulcer Index

Depth and duration of drawdowns from previous peaks

13.38%

18.71%

-5.33%

Volatility

MDGL vs. ELVA - Volatility Comparison

The current volatility for Madrigal Pharmaceuticals, Inc. (MDGL) is 13.71%, while Electrovaya Inc. Common Shares (ELVA) has a volatility of 27.27%. This indicates that MDGL experiences smaller price fluctuations and is considered to be less risky than ELVA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


MDGLELVADifference

Volatility (1M)

Calculated over the trailing 1-month period

13.71%

27.27%

-13.56%

Volatility (6M)

Calculated over the trailing 6-month period

31.76%

63.77%

-32.01%

Volatility (1Y)

Calculated over the trailing 1-year period

45.97%

84.18%

-38.21%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

133.37%

69.12%

+64.25%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

117.49%

86.10%

+31.39%

Dividends

MDGL vs. ELVA - Dividend Comparison

Neither MDGL nor ELVA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

MDGL vs. ELVA - Financials Comparison

This section allows you to compare key financial metrics between Madrigal Pharmaceuticals, Inc. and Electrovaya Inc. Common Shares. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0050.00M100.00M150.00M200.00M250.00M300.00M350.00M20222023202420252026
311.34M
17.80M
(MDGL) Total Revenue
(ELVA) Total Revenue
Values in USD except per share items

MDGL vs. ELVA - Profitability Comparison

The chart below illustrates the profitability comparison between Madrigal Pharmaceuticals, Inc. and Electrovaya Inc. Common Shares over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

0.0%20.0%40.0%60.0%80.0%100.0%20222023202420252026
91.4%
31.0%
Portfolio components
MDGL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Madrigal Pharmaceuticals, Inc. reported a gross profit of 284.49M and revenue of 311.34M. Therefore, the gross margin over that period was 91.4%.

ELVA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Electrovaya Inc. Common Shares reported a gross profit of 5.51M and revenue of 17.80M. Therefore, the gross margin over that period was 31.0%.

MDGL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Madrigal Pharmaceuticals, Inc. reported an operating income of -92.72M and revenue of 311.34M, resulting in an operating margin of -29.8%.

ELVA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Electrovaya Inc. Common Shares reported an operating income of 1.52M and revenue of 17.80M, resulting in an operating margin of 8.5%.

MDGL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Madrigal Pharmaceuticals, Inc. reported a net income of -94.39M and revenue of 311.34M, resulting in a net margin of -30.3%.

ELVA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Electrovaya Inc. Common Shares reported a net income of 1.00M and revenue of 17.80M, resulting in a net margin of 5.6%.


Frequently Asked Questions


MDGL and ELVA have a correlation of 0.10, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ELVA has higher volatility (27.27%) compared to MDGL (13.71%). In terms of maximum drawdown, MDGL dropped -98.40% vs ELVA's -96.90%.

ELVA currently has the higher Sharpe Ratio (2.00 vs 1.35), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for MDGL and ELVA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer